-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $26

Benzinga·03/31/2025 16:27:52
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $9 to $26.